Trap1在乳腺导管内增生性病变中的表达
| 作者: |
1卫颖泽,
1金晓霞,
1赵敏,
1杨书云,
1尹海兵
1 南通市肿瘤医院病理科，江苏 南通 226361 |
| 通讯: |
金晓霞
Email: jxxntu@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2021.09.004 |
| 基金: | 国家自然科学基金(81702634)；南通市科技计划项目(JC2019142)；南通市指导性计划项目(MSZ18144)。 |
摘要
目的：检测肿瘤坏死因子受体相关蛋白1(tumor necrosis factor receptor-associated protein 1，Trap1)在乳腺导管内增生性病变中的表达情况。方法：采用免疫组织化学方法检测Trap1在40例普通型导管增生(usual ductal hyperplasia，UDH)，13例不典型导管增生(atypical ductal hyperplasia，ADH)及50例导管原位癌(ductal carcinoma in situ，DCIS)中的表达情况。结果：Trap1在UDH中弱阳性、中等阳性、强阳性表达率分别为75%、25%、0%；Trap1在ADH中弱阳性、中等阳性、强阳性表达率分别为0%、61.5%、38.5%；Trap1在DCIS中弱阳性、中等阳性、强阳性表达率分别为0%、40%、60%；Trap1在UDH中表达明显低于ADH和DCIS(P<0.05)，Trap1在ADH和DCIS中的表达无差异(P>0.05)；雌激素受体(estrogen receptor，ER)在UDH中阴性表达率为80%，在DCIS中弥漫强阳性表达率为90%，Trap1与ER在UDH和DCIS中的表达均呈正相关(P<0.05)；ER在ADH中弥漫强阳性表达率为69.2%，与Trap1的表达无相关性(P>0.05)。结论：Trap1在UDH中表达明显低于ADH或DCIS，Trap1在UDH和DCIS中表达与ER呈正相关，有望成为鉴别UDH与ADH或DCIS的新指标。
关键词：
肿瘤坏死因子受体相关蛋白1；免疫组织化学；普通型导管增生；不典型导管增生；导管原位癌；雌激素受体
Expression of Trap1 in breast intraductal proliferative lesions
CorrespondingAuthor: JIN Xiaoxia Email: jxxntu@163.com
DOI: 10.3978/j.issn.2095-6959.2021.09.004
Foundation: This work was supported by the National Natural Science Foundation (81702634), the Science and Technology Project of Nantong (JC2019142), and the Guiding Plan Project of Nantong (MSZ18144), China.
Abstract
Objective: To evaluate the expression of tumor necrosis factor receptor-associated protein 1 (Trap1) in breast ductal proliferative lesions. Methods: The expression of Trap1 in usual ductal hyperplasia (UDH, n=40), atypical ductal hyperplasia (ADH, n=13), and ductal carcinoma in situ (DCIS, n=50) were detected by immunohistochemistry. Results: Weakly, moderately, and strongly positive expressions of Trap1 were noted in 75%, 25% and 0% of UDH, respectively. However, the percentages of weakly, moderately, and strongly positive Trap1 expressions in ADH were 0%, 61.5% and 38.5%, respectively. The percentages of weakly, moderately, and strongly positive Trap1 expressions in DCIS was 0%, 40% and 60%, respectively. In conclusion, the expression of Trap1 in UDH was significantly lower than that in ADH and DCIS (both P<0.05). No significant difference of Trap1 expression was observed between ADH and DCIS (P>0.05). The negative percentage of estrogen receptor (ER) in UDH was 80%. The percentage of diffuse strong positive expression of ER in DCIS was 90%. The expressions of ER and Trp1 in UDH and DCIS were positive correlation (P<0.05). The percentage of diffusely strongly positive expression of ER in ADH was 69.2%. No correlation between ER and Trap1 in ADH was found (P>0.05). Conclusion: The expression of Trap1 in UDH is significantly lower than that in ADH or DCIS and the expressions of Trap 1 in UDH and DCIS are positively correlated with ER. Trap1 is expected to be a new biomarker for distinguishing UDH from ADH or DCIS.
Keywords：
tumor necrosis factor receptor-associated protein 1; immunohistochemistry; usual ductal hyperplasia; atypical ductal hyperplasia; ductal carcinoma in situ; estrogen receptor